<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nrx Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/nrx-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Nrx Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nrx-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a35978dffbe2df10a296.webp</url>
      <title>Nrx Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-reports-positive-fda-office-of-generic-drugs-feedback-on-preservative-free-ketamine-program</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-reports-positive-fda-office-of-generic-drugs-feedback-on-preservative-free-ketamine-program</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>NRx has received a positive review letter (Discipline Review Letter) addressing Drug Quality requesting only “Minor” administrative changesNRx conducted a</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-welcomes-presidential-initiative-to-accelerate-approval-of-psychedelic-medications-to-treat-depression-ptsd-and-suicidality</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-welcomes-presidential-initiative-to-accelerate-approval-of-psychedelic-medications-to-treat-depression-ptsd-and-suicidality</guid>
      <pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
      <description>President Trump signed an Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026.The order directs acceleration of research and lowered barriers to approvals of psychedelic medications to treat depression, PTSD, and suicidality.NRx Pharmaceuticals has been awarded Fast Track designation and recently received FDA guidance anticipating NRx’s upcoming New Drug Application for NRX-100 (preservative free ketamine) to treat depression, including bipolar depressio</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-advances-robotic-enabled-transcranial-magnetic-stimulation-combined-with-neuroplastic-therapy-for-military-and-first-responder-applications</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-advances-robotic-enabled-transcranial-magnetic-stimulation-combined-with-neuroplastic-therapy-for-military-and-first-responder-applications</guid>
      <pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
      <description>Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-appointment-of-glenn-tyson-as-the-companys-first-chief-commercial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-appointment-of-glenn-tyson-as-the-companys-first-chief-commercial-officer</guid>
      <pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
      <description>Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-fda-labeling-alignment-for-nrxs-preservative-free-ketamine-application</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-fda-labeling-alignment-for-nrxs-preservative-free-ketamine-application</guid>
      <pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
      <description>NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product.</description>
    </item>
    <item>
      <title>Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/hope-therapeutics-an-nrx-pharmaceuticals-subsidiary-nasdaqnrxp-announces-strategic-partnership-with-emobot-to-integrate-its-ai-powered-depression-thermometer-across-its-interventional-psychiatry-network</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/hope-therapeutics-an-nrx-pharmaceuticals-subsidiary-nasdaqnrxp-announces-strategic-partnership-with-emobot-to-integrate-its-ai-powered-depression-thermometer-across-its-interventional-psychiatry-network</guid>
      <pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
      <description>Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered &quot;Depression Thermometer&quot; across its</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-reports-full-year-2025-results-and-highlights-key-regulatory-and-commercial-progress</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-reports-full-year-2025-results-and-highlights-key-regulatory-and-commercial-progress</guid>
      <pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
      <description>Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-24-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-24-2026</guid>
      <pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
      <description>WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-fda-bioequivalence-determination-by-office-of-generic-drugs-for-nrxs-preservative-free-ketamine-application</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-fda-bioequivalence-determination-by-office-of-generic-drugs-for-nrxs-preservative-free-ketamine-application</guid>
      <pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
      <description>Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA).FDA has advised NRx in</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-confirms-path-to-new-drug-application-with-real-world-data-and-broader-proposed-indication-for-nrx-100-ketamine-following-type-c-fda-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-confirms-path-to-new-drug-application-with-real-world-data-and-broader-proposed-indication-for-nrx-100-ketamine-following-type-c-fda-meeting</guid>
      <pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
      <description>NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and</description>
    </item>
    <item>
      <title>HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/hope-therapeutics-an-nrx-subsidiary-nasdaqnrxp-announces-opening-of-palm-beach-fl-clinic-offering-one-day-treatment-for-depression-and-ptsd</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/hope-therapeutics-an-nrx-subsidiary-nasdaqnrxp-announces-opening-of-palm-beach-fl-clinic-offering-one-day-treatment-for-depression-and-ptsd</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaq-nrxp-appoints-prof-joshua-brown-md-phd-as-chief-medical-innovation-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaq-nrxp-appoints-prof-joshua-brown-md-phd-as-chief-medical-innovation-officer</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the</description>
    </item>
    <item>
      <title>NRx Builds Momentum From FDA Progress To Strategic Expansion</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-builds-momentum-from-fda-progress-to-strategic-expansion</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-builds-momentum-from-fda-progress-to-strategic-expansion</guid>
      <pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
      <description>By Meg Flippin, Benzinga DETROIT, MICHIGAN - February 27, 2026 (NEWMEDIAWIRE) - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-path-to-new-drug-application-with-real-world-data-and-broader-proposed-indication-for-nrx-100-ketamine-following-type-c-fda-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-path-to-new-drug-application-with-real-world-data-and-broader-proposed-indication-for-nrx-100-ketamine-following-type-c-fda-meeting</guid>
      <pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
      <description>NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-120300570</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-120300570</guid>
      <pubDate>Fri, 16 Jan 2026 12:03:00 GMT</pubDate>
      <description>WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Annual Meeting”) on March 23, 2026 at 10:00 a.m. Eastern Time, in virtual-only format at https://www.cstproxy.com/nrxpharma/2026, and any adjournments or postponements thereof. The Company&apos;s Board of Directors (the “Board”) also set a record date of February 12, 2026</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-120300036</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-120300036</guid>
      <pubDate>Wed, 14 Jan 2026 12:03:00 GMT</pubDate>
      <description>NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression.Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical records-derived dataset.Previously presented preliminary analysis of a 20,000 patient subset documented rapid resolution of depression and suicidality with initiation of intravenous ketamine.Analyses sug</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-and-neurocare-group-ag-announce-joint-offering-of-neuroplastic-therapy-targeting-depression-ptsd-and-other-mental-health-afflictions</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-and-neurocare-group-ag-announce-joint-offering-of-neuroplastic-therapy-targeting-depression-ptsd-and-other-mental-health-afflictions</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo® Transcranial</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-elimination-of-all-balance-sheet-debt-following-equity-conversion</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nasdaqnrxp-announces-elimination-of-all-balance-sheet-debt-following-equity-conversion</guid>
      <pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
      <description>Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisionsCompany</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals (NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nrxp-amends-ind-to-advance-nrx-101-with-tms-for-depression-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-nrxp-amends-ind-to-advance-nrx-101-with-tms-for-depression-treatment</guid>
      <pubDate>Wed, 03 Dec 2025 19:30:00 GMT</pubDate>
      <description>LOS ANGELES, CA - December 3, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug filing for NRX-101 to include use of the drug in combination with Transcr...</description>
    </item>
    <item>
      <title>NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation</title>
      <link>https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-to-discuss-new-nrx-101-pipeline-indication-for-augmentation-of-transcranial-magnetic-stimulation</link>
      <guid isPermaLink="true">https://6ix.com/company/nrx-pharmaceuticals-inc/news/nrx-pharmaceuticals-to-discuss-new-nrx-101-pipeline-indication-for-augmentation-of-transcranial-magnetic-stimulation</guid>
      <pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
      <description>As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial</description>
    </item>
  </channel>
</rss>